<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5387">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036813</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-031</org_study_id>
    <nct_id>NCT03036813</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)</brief_title>
  <acronym>GBT_HOPE</acronym>
  <official_title>A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440
      Administered Orally to Patients With Sickle Cell Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double blind, parallel group, multicenter study of
      participants, age 12 to 65 years, with SCD. The key purpose for the study is to establish
      efficacy and safety of GBT440 as compared with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
    <masking_description>This study is a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin (Hb)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Proportion of participants with increase in Hb &gt;1 g/dL from Baseline to Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of days with SCD symptom exacerbation</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Calculated from Sickle Cell Disease Severity Measure (SCDSM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the SCDSM Total Symptom Score</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Calculated from SCDSM</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GBT440</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GBT440</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female study participants with sickle cell disease

          2. Participants have had at least 1 episode of vaso-occlusive crisis (VOC) in the past
             12 months.

          3. Age 12 to 65 years

          4. Hemoglobin (Hb) ≥6.0 and ≤10.5 g/dL during screening

          5. For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for
             at least 3 months prior to signing the ICF.

        Exclusion Criteria:

          1. More than 10 VOCs within the past 12 months that required a hospital, emergency room
             or clinic visit

          2. Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also
             termed chronic, prophylactic, or preventive transfusion) or have received a RBC
             transfusion for any reason within 28 days of signing the ICF

          3. Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of
             signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to
             signing the ICF)

          4. Hepatic dysfunction characterized by alanine aminotransferase (ALT) &gt;4 × upper limit
             of normal

          5. Severe renal dysfunction (estimated glomerular filtration rate at the Screening
             visit; calculated by the central laboratory) &lt;30 mL/min/1.73 m^2 or on chronic
             dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Lehrer-Graiwer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josh Lehrer-Graiwer, MD</last_name>
    <phone>650-741-7744</phone>
    <email>jlehrer@globalbloodtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki West</last_name>
      <phone>405-602-3939</phone>
      <email>nwest@LHSI.NET</email>
    </contact>
    <contact_backup>
      <last_name>Shelly Brunson, BS, CCRP</last_name>
      <phone>(405) 602-3927</phone>
      <email>Sbrunson@lhsi.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>January 27, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
